PET-scan in colorectal cancer.
After an introduction on the physical and biological basics of positron emission tomography, this paper reviews the current status of PET imaging using the glucose analogue FDG in colorectal cancer. The use of PET-FDG is reviewed for detection, initial staging, therapy monitoring and staging of disease relapse.
Lonneux
M
M
Department of Nuclear Medicine, Cliniques universitaires Saint-Luc, Brussels, Belgium. max.lonneux@imre.ucl.ac.be
D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D005947:Glucose